What is your current role in the project?
I joined the AMYPAD project in January 2019 as a postdoctoral researcher at the University of Geneva, as part of the team led by Prof Giovanni B Frisoni. As such, I am in charge of the analyses of the data collected in the Diagnostic and Patient Management Study (DPMS), a randomized controlled trial aiming to test the clinical utility and cost-effectiveness of amyloid PET in a controlled but realistic clinical setting.

What is your overall vision?
AMYPAD will supply European health professionals and healthcare payers with real-world data to improve the diagnostic workup and management of people suspected to have Alzheimer’s disease.

What do you find most challenging about the project?
AMYPAD is a multicentric project involving several European centers with different background. I think that one of its most challenging aspects consists of connecting and integrating different realities and perspectives.